Novacyt Saham

Novacyt EV/Pendapatan

EV/Pendapatan (Nilai Perusahaan terhadap Pendapatan) dari Novacyt (ALNOV.PA) pada 15 Agu 2026 adalah 0,33. Tahun sebelumnya, EV/Pendapatan (Nilai Perusahaan terhadap Pendapatan) adalah -0,43 — perubahan sebesar -176,51% (lebih tinggi).

EV/Pendapatan

0,33

YoY

-176,51%

Terakhir Diperbarui:

EV/Pendapatan (Nilai Perusahaan terhadap Pendapatan) dari Novacyt adalah 2026 0,33 . EV/Pendapatan (Nilai Perusahaan terhadap Pendapatan) dari Novacyt adalah 2025 -0,43 . Menurun -176,51% lebih tinggi dibandingkan dengan tahun sebelumnya.
Access this data via the Eulerpool API

Novacyt Analisis saham

Apa yang dilakukan Novacyt? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt adalah salah satu perusahaan paling populer di Eulerpool.

Pertanyaan yang Sering Diajukan tentang saham Novacyt

EV/Pendapatan (Nilai Perusahaan terhadap Pendapatan) Novacyt adalah 0,33 pada tahun 2026.

EV/Pendapatan (Nilai Perusahaan terhadap Pendapatan) dari Novacyt berubah dari -0,43 menjadi 0,33, mewakili perubahan -176,51%. Nilainya lebih tinggi daripada tahun sebelumnya.

Di Eulerpool Anda dapat menemukan perkembangan historis lengkap EV/Pendapatan (Nilai Perusahaan terhadap Pendapatan) Novacyt sejak 2006 – dengan nilai tahunan, bagan, dan analisis detail.

Rasio EV/Pendapatan membandingkan nilai perusahaan dengan total pendapatan. Rasio ini sangat berguna untuk menilai perusahaan pertumbuhan tinggi yang mungkin belum menguntungkan.

Untuk mengevaluasi EV/Pendapatan (Nilai Perusahaan terhadap Pendapatan), sangat penting untuk membandingkannya dengan perusahaan sejenis di industri dan sektor yang sama. Di Eulerpool, Anda dapat menemukan perbandingan industri langsung untuk EV/Pendapatan (Nilai Perusahaan terhadap Pendapatan).

Nilai '' yang 'baik' bervariasi menurut industri dan tahap perusahaan. Di Eulerpool, Anda dapat membandingkan Novacyt EV/Pendapatan (Nilai Perusahaan terhadap Pendapatan) dengan pesaing sektor dan rata-rata industri untuk menilai apakah menarik.

Access this data via the Eulerpool API

Penilaian — Novacyt

Semua Metrik Kunci — Novacyt